Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
rFVIIIFc Immune Tolerance Induction in Severe Hemophilia A With Inhibitors (Japan cohort of 997HA402)
jRCTs051180197Completed
- Sponsor
- Bioverativ Inc.
- Start
- Dec 2018
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
01
Overview
Open-label, single-arm trial of eftrenonacog alfa in hemophilia A, sponsored by Bioverativ Inc. Primary endpoint: Time to tolerization. Started Dec 2018; status: completed.
02
Drugs
eftrenonacog alfa
03
Conditions
hemophilia A
Beyond the preview
Go deeper on jRCTs051180197.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs051180197.